title: Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice.
abstract: Vaccination with leishmanial Ag and CpG oligodeoxynucleotides (ODN) confers sustained cellular immunity and protection to infectious challenge up to 6 mo after immunization. To define the cellular mechanism by which CpG ODN mediate their adjuvant effects in vivo, the functional capacity of distinct dendritic cell (DC) subsets was assessed in the lymph nodes (LNs) of BALB/c mice, 36 h after immunization with the leishmanial antigen (LACK) and CpG ODN. After this immunization, there was a striking decrease in the frequency of the CD11c+B220+ plasmacytoid DCs with a proportionate increase in CD11c+CD8-B220- cells. CD11c+CD8+B220- cells were the most potent producers of interleukin (IL)-12 p70 and interferon (IFN)-gamma, while plasmacytoid DCs were the only subset capable of secreting IFN-alpha. In terms of antigen presenting capacity, plasmacytoid DCs were far less efficient compared with the other DC subsets. To certify that DCs were responsible for effective vaccination, we isolated CD11c+ and CD11c- cells 36 h after immunization and used such cells to elicit protective immunity after adoptive transfer in naive, Leishmania major susceptible BALB/c mice. CD11c+ cells but not 10-fold higher numbers of CD11c- cells from such immunized mice mediated protection. Therefore, the combination of LACK antigen and CpG ODN adjuvant leads to the presence of CD11c+ DCs in the draining LN that are capable of vaccinating naive mice in the absence of further antigen or adjuvant.
authors.affiliation: VRC, NIAID, 40 Convent Dr., Room 40/3512, NIH, Bethesda, MD 20892, USA.
authors.forename: Javeed A
authors.initials: JA
authors.lastname: Shah
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Darrah
authors.forename: David R
authors.initials: DR
authors.lastname: Ambrozak
authors.forename: Tara N
authors.initials: TN
authors.lastname: Turon
authors.forename: Susana
authors.initials: S
authors.lastname: Mendez
authors.forename: Joanna
authors.initials: J
authors.lastname: Kirman
authors.forename: Chang-You
authors.initials: CY
authors.lastname: Wu
authors.forename: Nicolas
authors.initials: N
authors.lastname: Glaichenhaus
authors.forename: Robert A
authors.initials: RA
authors.lastname: Seder
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D001483:Base Sequence; D039521:CD11c Antigen / Q000276:immunology; D003713:Dendritic Cells / Q000145:classification / Q000276:immunology*; D015226:Dinucleoside Phosphates / Q000276:immunology*; D005260:Female; D016219:Immunotherapy, Adoptive / Q000379:methods; D018320:Leishmania major / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000276:immunology* / Q000517:prevention & control; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use; D014612:Vaccines / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D000953:Antigens, Protozoan; D039521:CD11c Antigen; D015226:Dinucleoside Phosphates; D009838:Oligodeoxyribonucleotides; D014612:Vaccines; C015772:CpG dinucleotide